Blog re NOX-KZA agreement, page-5

This whole business with the two companies, has the makings of a great story in something like the Financial Review......with the theme that Dr Kelly may again take the helms of the old Novogen cancer drug platform.

The size of NOX compared to KZA and the fact that both companies are undertaking studies on the same drug.....I think means that sooner or later, some form of merge will logically have to take place. Dr Kelly is the person who runs the $100m company and KZA is valued at just over $20m....... It seems from the Clinical/Trials gov website, NOX also now has access to the superbenzopyran drug platform.ie Cantrixil.

Its a great coup today to gain unrestricted access to the platform of drugs that he was instrumental in discovering many years ago......I think however, the last thing on the minds of either management team right now, is any thoughts of coming together.

Collaboration is the word that have BOTH used.....that means each developing trials and programs for mutual benefit. (NOX rectal administration / radiology / diverse cancer types...... v..... KZA Intraperitoneal chemo / the most diverse and difficult of all cancers - ovarian cancer

From the point of view of a KZA shareholder - why on earth is there such a difference in the capitalisation of both companies. (KZA also carrying $160m in tax loses).

The significance of that 20 Nov, NOX announcement.....I think is not understood. There is no drug that can stabilise late stage 4 cancer patients, however that announcements suggests the way cancer is treated may be changing.